OF 1

Discontinued Product

5289 has been discontinued.

View all Bromodomains products.
Description: Selective BRPF1B and BRPF2 inhibitor
Chemical Name: 4-Bromo-N-(2,3-dihydro-6-methoxy-1,3-dimethyl-2-oxo-1H-benzimidazol-5-yl)-2-methylbenzenesulfonamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (4)

Biological Activity for OF 1

OF 1 is a selective BRPF1B and BRPF2 bromodomain inhibitor (Kd values are 100 and 500 nM respectively). Exhibits 39-fold selectivity for BRPF1B and BRPF2 over BRD4. Accelerates FRAP recovery at 5 μM in a BRPF2 FRAP assay. Inhibits RANKL-induced differentiation of primary murine bone marrow cells and human primary monocytes into osteoclasts.

Licensing Information

This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the OF 1 probe summary on the SGC website.

Compound Libraries for OF 1

OF 1 is also offered as part of the Tocriscreen Epigenetics Library. Find out more about compound libraries available from Tocris.

Technical Data for OF 1

M. Wt 440.31
Formula C17H18BrN3O4S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 919973-83-4
PubChem ID 35397514
InChI Key YUNQZQREIHWDQT-UHFFFAOYSA-N
Smiles CN1C2=C(C=C(OC)C(NS(C3=C(C)C=C(Br)C=C3)(=O)=O)=C2)N(C)C1=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for OF 1

References are publications that support the biological activity of the product.

Meier et al (2017) Selective targeting of bromodomains of the bromodomain-PHD fingers family impairs osteoclast differentiation. ACS Chem.Biol. 12 2619 PMID: 28849908

View Related Products by Target

View Related Products by Product Action

View all Bromodomain Inhibitors

Keywords: OF 1, OF 1 supplier, OF1, selective, BRPF1B, BRPF2, bromodomain, inhibitors, inhibits, epigenetics, Bromodomains, 5289, Tocris Bioscience

Citations for OF 1

Citations are publications that use Tocris products.

Currently there are no citations for OF 1.

Reviews for OF 1

There are currently no reviews for this product. Be the first to review OF 1 and earn rewards!

Have you used OF 1?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Stem Cell Research Product Guide

Stem Cell Research Product Guide

This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:

  • Self-renewal and Maintenance
  • Differentiation
  • Reprogramming
  • Organoid Generation
  • GMP and Ancillary Material Grade Products
Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.